L2M-LigandQI: Accelerating drug discovery with quantum-powered insight

This project will launch LigandQI, a next-generation Contract Research Organization (CRO) that empowers researchers in the pharmaceutical and biotechnology sectors with advanced molecular-interaction analysis. LigandQI applies state-of-the-art quantum chemistry and computational modeling to reveal, with exceptional precision, how drug candidates bind to their target proteins, enabling faster, more accurate lead optimization. Through the Lab2Market Launch program, the team will identify pilot partners, demonstrate the scientific and commercial value of its services, and secure its first industry contract. By supporting the creation of this deep-tech venture, DMZ Ventures will help establish a Canadian CRO that bridges cutting-edge science and industry needs, accelerating drug discovery and strengthening Canadas global leadership in health innovation.

Faculty Supervisor:

Stijn De Baerdemacker

Student:

Partner:

DMZ Ventures Inc

Discipline:

Life Sciences

Sector:

Professional, scientific and technical services

University:

University of New Brunswick

Program: